You are here

  • Home
  • Archive
  • Volume 30, Issue Suppl 3
  • 138 Phase 1 dose-escalation study of STRO-002, an anti-folate receptor alpha (FRα) antibody drug conjugate (ADC), in patients with advanced platinum-resistant/refractory epithelial ovarian cancer (OC)

Article metrics

Article menu

Download PDFPDF

Poster
IGCS20_1113
138 Phase 1 dose-escalation study of STRO-002, an anti-folate receptor alpha (FRα) antibody drug conjugate (ADC), in patients with advanced platinum-resistant/refractory epithelial ovarian cancer (OC)
Free

 

Online download statistics by month:

Online download statistics by month: November 2020 to April 2024

AbstractFullPdf
Nov 202036025
Dec 202016010
Jan 20212009
Feb 20211104
Mar 20212507
Apr 20211405
May 2021303
Jun 2021505
Jul 2021106
Aug 2021108
Sep 2021304
Oct 202118021
Nov 202129021
Dec 20212603
Jan 20223203
Feb 20228608
Mar 20225207
Apr 20225305
May 202230010
Jun 20221905
Jul 20224302
Aug 20223405
Sep 20224008
Oct 20222803
Nov 202212601
Dec 20224507
Jan 20232803
Feb 20232606
Mar 20232804
Apr 20233503
May 20232903
Jun 20232102
Jul 20231203
Aug 20232402
Sep 20231204
Oct 20232904
Nov 20234604
Dec 20234101
Jan 2024800
Feb 20242402
Mar 20246802
Apr 20241301
Total12400239